Industrial Biotechnology Innovation Cluster

产业生物技术创新集群

• 批准号: EP/Y024168/1
• 负责人: Aline Miller
• 金额: $ 666.83万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY024168%2F1
• 关键词: Industrial; Biotechnology; Innovation; Cluster

Industrial Biotechnology (IB) is a set of cross-disciplinary technologies that uses biological resources for producing and processing everyday products such as food, fuels, and medicines. The field is poised for dramatic growth and has the potential to disrupt markets worth more than £34bn in the UK alone. A confluence of consumer demand, Government carbon emission targets, feedstock production efficiencies, fundamental and technical innovation has created a perfect situation for the industry to significantly expand. This paradigm shift capitalises on the strengths of a vast range of scientific and engineering disciplines which form the foundation for leveraging the rapid, specialised, and competitive growth of the sector. Industrial Biotechnology is an area in which the North-West (NW) of England has critical mass and is rapidly emerging as a world leading cluster. The region is home to some of the world's biggest healthcare and biomanufacturing companies, including AstraZeneca, Teva, Croda and Unilever, and the first commercial production of a biologic was in Speke with Eli Lilly's manufacture of insulin. The NW is home to several SME innovation zones, including Daresbury, Liverpool Knowledge Quarter and Alderley Park, which is the UK's largest single site life science campus. IB in the region employs 25,000 people and has a turnover of over £6Bn. The HEI sector is also thriving and recognised for its internationally leading IB research and unique facilities, purpose-built for innovation. Most recently demonstrated by the University of Manchester's Queens Anniversary Prize for higher education, which recognised the world-leading biotechnology expertise of the Manchester Institute of Biotechnology that sign-posts towards a bio industrial revolution. Translating IB to meet urgent societal needs will not happen spontaneously; an integrated strategy, cluster of translational activity and innovation ecosystem are essential. The NW has co-location of organisations, knowledge, skills and facilities which have already demonstrated they can promote connection and collaboration - enabling those in the region to operate more flexibly and productively. Here, we will concentrate and build our regional strengths in academia, business, civic partners, accelerators, investors and creatives with civil society and establish the Industrial Biotechnology Innovation Cluster (IBIC) with the aim of accelerating commercial exploitation of our outputs and delivering economic, social and scientific impact. United by a culture of ethics, diversity, and openness, the cluster will provide businesses with access to cutting-edge R&D knowledge, capabilities and infrastructure as well as innovation finance, skills training, and specialist support and advice. IBIC will be led by The University of Manchester and headquartered in the new Innovation District in Manchester - at the heart of the north's growing economy. It has been co-created with the University of Liverpool and our wider Civic and Business Partners. It is fully aligned with Greater Manchester and Liverpool Civic Partners strategies to increase the benefit and accelerate the impact of fundamental research across the region, and more broadly the UK economy and society. IBIC will enable the UK to realise its ambition to be a global biotechnology research and innovation superpower. The IBIC is expected to directly stimulate £2.5M cash and £4M in-kind co-investment, establish 150 collaborative projects, train 200+ students to enter careers within IB, create up to 100 green jobs, and establish 20+ new commercial ventures attracting a further £10M in investment to the North-West, generating as a minimum 3:1 economic return to public investment over the medium term. It will have a long-term legacy by helping establish IBIC as an independent and business-led cluster of excellence and by enabling society to overcome challenges in energy security, disease, and hunger mitigation.

工业生物技术（IB）是一组跨学科技术，它使用生物资源来生产和加工每天的产品，例如食品，燃料和药品。该领域因急剧增长而毒害，仅在英国就破坏了价值超过34亿英镑的市场。消费者需求，政府碳排放目标，原料生产能力，基本和技术创新的融合为行业带来了一个理想的情况。这种范式将资本转移到了广泛的科学和工程学科的优势上，这是利用该行业快速，专业和竞争增长的基础。工业生物技术是英格兰西北部（NW）具有临界质量的领域，并且正在迅速成为世界领先的集群。该地区是世界上一些最大的医疗保健和生物制造公司的所在地，包括阿斯利康，Teva，Croda和Unilever，并且与Eli Lilly的胰岛素制造一起在Speke中首次在Speke中进行了商业生产。西北地区是几个中小企业创新区的所在地，包括达内斯伯里（Daesbury），利物浦知识季度和阿尔德利公园（Alderley Park），这是英国最大的单个现场生活科学校园。该地区的IB员工25,000人，营业额超过60亿英镑。 HEI部门还因其国际领先的IB研究和独特的设施而蓬勃发展，并为创新而设计。最近，曼彻斯特大学皇后区高等教育奖的表明，该奖项认可了曼彻斯特生物技术学院的世界领先的生物技术专家，该专家向生物工业革命提供了迹象。翻译IB以满足紧急社会需求不会自发发起人；综合策略，翻译活动和创新生态系统群是必不可少的。西北有组织，知识，技能和设施的共同设置，这些组织已经证明他们可以促进联系和协作 - 使该地区的人员能够更加灵活，更有效地运作。在这里，我们将集中并建立我们在学术界，商业，公民合作伙伴，加速器，投资者和创意者与民间社会的优势，并建立工业生物技术创新集群（IBIC），以加速商业利用我们的产出并产生我们的产出并带来经济，社会和科学影响。该集群通过道德，多样性和开放性的文化结合，将为企业提供尖端的研发知识，能力和基础设施以及创新融资，技能培训以及专业支持和建议和建议。 IBIC将由曼彻斯特大学领导，总部位于曼彻斯特新创新区 - 北方经济不断增长的核心。它与利物浦大学以及我们更广泛的公民和商业伙伴共同创建。它与大曼彻斯特和利物浦公民合作伙伴的战略完全保持一致，以提高利益并加速整个地区的基本研究的影响，更广泛地是英国的经济和社会。 IBIC将使英国能够实现其野心成为全球生物技术研究和创新超级大国。预计该国际足联将直接刺激250万英镑的现金和400万英镑的实物共同投资，建立了150个合作项目，培训200多个学生在IB内进入职业，创造了多达100个绿色工作岗位，并建立了20多个新的商业企业，吸引了1000万英镑的投资到North-west，以最低限度的经济投资，从而超过公众投资。它将通过帮助建立无权建立独立和商业领导的卓越群体，并使社会能够克服能源安全，疾病和缓解饥饿方面的挑战，从而具有长期的遗产。